{
  "relevance_rule": {
    "rule_text": "All abstracts that have client provided keywords",
    "approach": "keywords",
    "key_concepts": {
      "keywords": [
        "Hyperphosphatemia",
        "Parathyroid hormone",
        "Calcitriol",
        "Chronic kidney disease",
        "ESRD",
        "Phosphate binder",
        "Sevelamer",
        "sucroferric oxyhydroxide",
        "lanthanum carbonate",
        "Ferric citrate",
        "Calcium acetate",
        "Constipation",
        "Tenapanor",
        "Claudins",
        "FGF receptor",
        "Albuminuria",
        "nicotinamide",
        "vitamin D",
        "SGLT2 inhibitors",
        "canagliflozin",
        "Dapagliflozin",
        "Empagliflozin",
        "Ozempic",
        "Calcium carbonate",
        "Serum phosphate",
        "Phosphate",
        "Fibroblast growth factor 23",
        "Hemodialysis",
        "Dialysis",
        "Dialysis Outcomes and Practice Patterns Study",
        "Sodium hydrogen transport exchanger 3",
        "sodium-dependent phosphate cotransporter 2b",
        "KDIGO",
        "KDOQI",
        "Sodium",
        "Phosphorus",
        "Klotho",
        "Tight junctions",
        "Occludins",
        "Vascular calcification",
        "Bristol Stool Form Scale",
        "Interdialytic weight gain",
        "peritoneal dialysis",
        "NTX1942",
        "SLC34A2",
        "Glomerular",
        "CKD-MBD",
        "Smooth muscle calcification",
        "Oxylanthanum carbonate"
      ],
      "categories": [],
      "contextual_concepts": []
    },
    "reasoning": "This rule explicitly states that relevance is determined by the presence of client provided keywords."
  },
  "priority_rules": [
    {
      "priority": "High",
      "rule_text": "Phase 2 data, Phase 3 data (including meta-analyses), real-world data (including PROs and registry data), Phosphate binders/phosphate lowering treatment; EXCLUDE Ardelyx sponsored abstracts",
      "approach": "hybrid",
      "key_concepts": {
        "keywords": [
          "Phase 2",
          "Phase 3",
          "meta-analysis",
          "real-world data",
          "PROs",
          "registry data",
          "Phosphate binder",
          "phosphate lowering treatment"
        ],
        "categories": [
          "Clinical trial phase",
          "Treatment type"
        ],
        "contextual_concepts": [
          "patient reported outcomes",
          "registry studies",
          "meta-analyses"
        ]
      },
      "exclusions": [
        "Ardelyx sponsored"
      ],
      "reasoning": "This rule requires both keyword matching for phases and treatments, and context for real-world data and meta-analyses. Ardelyx sponsored abstracts are excluded to ensure mutual exclusivity with the Internal priority."
    },
    {
      "priority": "Internal",
      "rule_text": "Ardelyx sponsored abstracts; EXCLUDE Phase 2, Phase 3, meta-analyses, real-world data, PROs, registry data, Phosphate binders/phosphate lowering treatment",
      "approach": "keywords",
      "key_concepts": {
        "keywords": [
          "Ardelyx sponsored"
        ],
        "categories": [
          "Sponsorship"
        ],
        "contextual_concepts": []
      },
      "exclusions": [
        "Phase 2",
        "Phase 3",
        "meta-analysis",
        "real-world data",
        "PROs",
        "registry data",
        "Phosphate binder",
        "phosphate lowering treatment"
      ],
      "reasoning": "This rule is based on sponsorship keyword and excludes all High priority concepts to maintain exclusivity."
    },
    {
      "priority": "Medium",
      "rule_text": "Phase 1 data, retrospective analyses, prognostic studies, trial designs, preclinical studies; studies with trial outcomes and endpoints; other general studies; EXCLUDE Ardelyx sponsored abstracts, Phase 2, Phase 3, meta-analyses, real-world data, PROs, registry data, Phosphate binders/phosphate lowering treatment",
      "approach": "hybrid",
      "key_concepts": {
        "keywords": [
          "Phase 1",
          "retrospective analysis",
          "prognostic study",
          "trial design",
          "preclinical study",
          "trial outcomes",
          "endpoints"
        ],
        "categories": [
          "Study type",
          "Trial phase"
        ],
        "contextual_concepts": [
          "general studies"
        ]
      },
      "exclusions": [
        "Ardelyx sponsored",
        "Phase 2",
        "Phase 3",
        "meta-analysis",
        "real-world data",
        "PROs",
        "registry data",
        "Phosphate binder",
        "phosphate lowering treatment"
      ],
      "reasoning": "This rule covers a broad set of study types and outcomes, requiring both keyword and context matching, and excludes higher priority concepts for exclusivity."
    },
    {
      "priority": "Low",
      "rule_text": "All abstracts that only have mention of an indication and does not include any other data; EXCLUDE Ardelyx sponsored abstracts, Phase 1, Phase 2, Phase 3, meta-analyses, real-world data, PROs, registry data, Phosphate binders/phosphate lowering treatment, retrospective analyses, prognostic studies, trial designs, preclinical studies, trial outcomes, endpoints, general studies",
      "approach": "context",
      "key_concepts": {
        "keywords": [],
        "categories": [
          "Indication only"
        ],
        "contextual_concepts": [
          "no data",
          "mention only"
        ]
      },
      "exclusions": [
        "Ardelyx sponsored",
        "Phase 1",
        "Phase 2",
        "Phase 3",
        "meta-analysis",
        "real-world data",
        "PROs",
        "registry data",
        "Phosphate binder",
        "phosphate lowering treatment",
        "retrospective analysis",
        "prognostic study",
        "trial design",
        "preclinical study",
        "trial outcomes",
        "endpoints",
        "general studies"
      ],
      "reasoning": "This rule requires semantic/contextual analysis to determine if only an indication is mentioned without any supporting data, and excludes all higher priority concepts."
    }
  ]
}